The Hobbling of China's Drug-Review Revamp

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING: ByteDance Targets July Launch of Upgraded AI Video Model; Embodied AI Startup Kunlunxing Lands Multibillion Yuan Raise; Europe Has a Lot to Learn From China About Electric Trucks, Volvo CTO Says

LATEST: Europe Has a Lot to Learn From China About Electric Trucks, Volvo CTO Says; Embodied AI Startup Kunlunxing Lands Multibillion Yuan Raise; ByteDance Targets July Launch of Upgraded AI Video Model; China’s Starlink Challenger Seeks Up to $2.2 Billion for Satellite Network Push; New Model Propels Zhipu AI’s Market Value to Record HK$1 Trillion; In AI Pitch, Alibaba Chairman Urges Europe to Look Beyond U.S. Tech; Cover Story: China’s AI Boom Is Rewiring Its Power Grid; In Depth: How AI Is Rewiring White-Collar Work in China; Chipmaker YMTC Cedes Control of Foundry Unit Ahead of Mega IPO; Chinese Startup Manifold AI Raises Fresh Funding as Investors Bet on ‘World Models’; Crealights Takes Step Closer to Hong Kong IPO as Data Center Boom Fuels Growth Prospects; Tencent Lets AI Agent Make Purchases Through WeChat Pay; Galaxea AI Chief Says China Could Lead Robotics Models Within Three Years; SiliconFlow Raises $294 Million as China’s AI Inference Demand Surges; Ant Revamps Alipay With AI Assistant in Biggest App Overhaul; New Model Sends Zhipu AI’s Stock Soaring; DJI, Insta360 File Competing U.S. Patent Lawsuits Over Camera Tech; Cover Story: When Employees Leave, Their AI Clones Carry on Working; AI Stocks Zhipu, MiniMax Slide as Lock-Up Expirations Near; Japan’s Chip Exports to China Surge as Bilateral Trade Rebounds

By Tanner Brown / Jun 10, 2019 10:23 AM / Economy

Photo: VCG

China is failing to adequately fund its drug evaluation agency — and that is undermining its push to accelerate new drug approvals, enhance industry supervision and make its drug review system compatible with global standards.

Read the full report here in Caixin’s In Depth: Why China’s Drug-Review Revamp Is Stalling

Share this article

Open WeChat and scan the QR code